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BACKGROUND: The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) is the largest cancer screening pro-
gram for low-income women in the United States. This study updates previous estimates of the costs of delivering preventive cancer
screening services in the NBCCEDP. METHODS: We developed a standardized web-based cost-assessment tool to collect annual
activity-based cost data on screening for breast and cervical cancer in the NBCCEDP. Data were collected from 63 of the 66 pro-
grams that received funding from the Centers for Disease Control and Prevention during the 2006/2007 fiscal year. We used these
data to calculate costs of delivering preventive public health services in the program. RESULTS: We estimated the total cost of all
NBCCEDP services to be $296 (standard deviation [SD], $123) per woman served (including the estimated value of in-kind donations,
which constituted approximately 15% of this total estimated cost). The estimated cost of screening and diagnostic services was $145
(SD, $38) per women served, which represented 57.7% of the total cost excluding the value of in-kind donations. Including the value
of in-kind donations, the weighted mean cost of screening a woman for breast cancer was $110 with an office visit and $88 without,
the weighted mean cost of a diagnostic procedure was $401, and the weighted mean cost per breast cancer detected was $35,480.
For cervical cancer, the corresponding cost estimates were $61, $21, $415, and $18,995, respectively. CONCLUSIONS: These NBCCEDP
cost estimates may help policy makers in planning and implementing future costs for various potential changes to the program.
Cancer 2014;120(16 suppl):2604-11. VC 2014 American Cancer Society.
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INTRODUCTION
In the United States, screening for breast and cervical cancer is recommended by the U.S. Preventive Services Task Force.1
Screening for these cancers has been reported to be effective in reducing morbidity andmortality associated with these can-
cers through early detection and treatment.2,3
Despite evidence showing a modest decrease in incidence and mortality rates associated with breast and cervical can-
cers,4 little progress has been achieved in increasing screening rates for these cancers over the last decade.5 In addition,
screening rates have been substantially lower than the national average among low-income women who are uninsured or
underinsured,6,7 and these women have been found to be more likely to present with advanced-stage cancer than privately
insured women.7,8 To reduce disparities in cancer mortality rates and provide low-income uninsured women with greater
access to cancer screening and diagnostic services, in 1990 the US Congress passed the Breast and Cervical Cancer Mortal-
ity Prevention Act (Public Law 101-354). Detailed descriptions of this law and of the National Breast and Cervical Cancer
Early Detection Program (NBCCEDP), which was formed as a result of it, have been presented previously9 and are also
provided elsewhere in this Supplement.10 Since 2000, with the implementation of the Breast and Cervical Cancer Preven-
tion and Treatment Act, women diagnosed with cancer through the NBCCEDP are enrolled in state Medicaid programs
to receive treatment.
As the largest organized cancer screening program in the United States, the NBCCEDP is a complex system of 68
individual screening programs, each with its own service delivery model. Because of this diversity of service delivery models,
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the operating efficiency of each screening program within
the NBCCEDP needs to be assessed separately. In 2005,
we began to systematically collect cost data to comprehen-
sively address economic issues related to the NBCCEDP.
The NBCCEDP cost estimates presented in this article
update and extend previously published estimates of the
costs of delivering cancer screening services through the
NBCCEDP during the 2003/2004 fiscal year.9
MATERIALS AND METHODS
Study Population and Definitions
The previous study of NBCCEDP service costs was based
on data collected from only 9 program grant recipients.9
This study is based on data collected from 63 of the 66
grantees that received Centers for Disease Control and
Prevention (CDC) funding during the 2006/2007 fiscal
year. On the basis of these data, we calculated the follow-
ing 8 outcomes: 1) the mean and median number of
women served and the associated total program costs, 2)
the cost per woman served with and without in-kind don-
ations, 3) the cost per woman served for clinical services,
4) the cost per woman screened for breast and cervical
cancer with and without office visits, 5) the cost per case
of cancer detected, 6) the cost of diagnostic procedures
performed during an office visit, 7) the cost and percent
distribution per woman served by each program compo-
nent, and 8) the relationship between the average cost per
woman served and the number of women served by the
various grant recipients.
In our analyses, “women served” referred to women
who received a screening test in the program plus women
who received a screening test outside the program but
were referred to the program for a diagnostic procedure;
“cost per woman served” referred to the cost of screening a
woman in the program plus the cost of diagnostic proce-
dure for a woman who was screened outside the program
but was referred to the program at a diagnostic stage;
“women screened” referred only to those who received a
screening test through the NBCCEDP; “screening serv-
ices” referred to either mammography and clinical breast
examination for breast cancer screening or a Papanicolaou
(Pap) test for cervical cancer screening; and “in-kind don-
ations” referred to our estimates of the value of the time of
volunteers and the value of donated materials for which
an NBCCEDP grantee did not have to pay. We included
the estimated value of these “free” resources in some of
our cost estimates so that the estimates would reflect the
full economic cost of providing cancer screening services
in the NBCCEDP.
CAT Development and Data Collection
To adequately collect economic costs related to
NBCCEDP, we developed a cost assessment tool (CAT).
The CAT is a standardized web-based instrument
designed to collect activity-based cost data from the
NBCCEDP (or other cancer screening programs). Details
of the development of this tool and an overview of its 11
modules have been presented previously.11 Figure 1 sum-
marizes the process used to obtain primary data for this
study, which included developing the CAT, developing
training materials to train grantees on how to use the
CAT to collect cost data in their respective programs.
Figure 1. Summary of CAT Development and Activity-Based
Cost Data Collection Process.
*The 11 modules in CAT are: 1) Grantee details; (2) Total funding;
(3) In-kind contribution, (4) Personnel expenditure: (5) Consultant
expenditure; (6) Screening expenditure; (7) Expenditure for non-
screening activities performed by health departments/centers or
providers; (8) Expenditures associated with contracts, materials,
travel and services; (9) Administrative expenditures; (10)
Resource allocation to breast versus cervical cancer screening for
selected activities; and (11) Screening and diagnostic activities
supported through the use of non-federal funds.
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We used the CAT to collect cost data for the 2006/
2007 fiscal year. Program activities and costs related to all
funding sources, including the CDC and state and other
organizations, were collected in the CAT and reported in
this study. Data were collected for clinical and health pro-
motion activities from each NBCCEDP grantee. “Clinical
activities” referred to screening, diagnostic follow-up for
abnormal results and referral for treatment. “Health pro-
motion activities” referred to activities related to program
management, patient support/casemanagement, dataman-
agement, quality assurance and improvement, partnerships,
professional development, recruitment, public education,
program evaluation, and administration. We also collected
data on the number of women screened and served by
NBCCEDP grantees with the use of non-CDC funds as
well as with the use of CDC funds.
Data Quality Review and Control
We performed the following steps to ensure the accuracy
of data collected with the CAT: 1) checked to ensure that
all CAT modules were fully and accurately completed; 2)
reviewed records to ensure that data submitted with the
CAT agreed with information grantees provided to CDC
in their financial status report; 3) requested that grantees
report all funds used in the program, including non-CDC
funds received from various sources; 4) reviewed the sub-
mitted data to determine whether grantees reported their
actual total expenditures for clinical (screening and diag-
nostic) procedures rather than their rates per procedure;
and 5) checked to ensure that grantees did not double-
report cost data. For grantees with incomplete or inaccu-
rate data, we conducted several rounds of follow-up tele-
phone calls to clarify inconsistencies, and in some cases we
required grantees to resubmit their data. We excluded
data from 3 grantees that did not meet our data quality
criteria, leaving us with data from 63 grantees for our
analysis.
Program Outcome Measures
We obtained the following program outcome measures
from the NBCCEDP surveillance database and the
CDC CAT for non-CDC funded screens: 1) the number
of women screened for breast cancer and the number
screened for cervical cancer with and without CDC
funds, 2) the number of women served in the program
with and without CDC funds, and 3) the number of
breast and cervical cancer cases and precancerous tumors
detected. Breast cancer cases include invasive cancer and
carcinoma in situ (CIS), whereas cervical cancer cases
include invasive tumors, high-grade cervical intraepithe-
lial neoplasia (CIN; ie, CIN2, CIN3, or CIS), and ade-
nocarcinoma in situ.
Data Analysis
The data collected in the CAT and the NBCCEDP sur-
veillance database were analyzed using Stata v10 (Stata,
College Station, TX). The analysis was conducted from a
program perspective; therefore, the article only examines
direct costs of providing preventive cancer screening serv-
ices and diagnostic procedures to the women participating
in the program. Because the study was conducted during a
1-year period, we did not discount costs and outcome
measures.
Calculating Program Costs
Costs were calculated with and without in-kind donations.
For all cost calculations, we present the arithmetic mean,
the weighted mean, and the median. Using the arithmetic
mean and median, we first calculated the total number of
women served per program, the cumulative number of
women screened with and without CDC funds, the num-
ber of women who received diagnostic follow-up proce-
dures for abnormal results, and the number of cancer cases
detected by stage. To express variation across programs, we
calculated the standard deviation (SD) for reported means
and interquartile ranges surrounding the medians. These
calculations were performed separately for breast and for
cervical cancer, respectively. Second, we calculated mean
and median values for program costs in a similar manner.
Third, we calculated the weighted mean cost of providing
preventive health services weighted by the number of
women served or screened in each program. We also used
weighted mean values to estimate cost per woman served
by program component as well as the corresponding per-
cent distribution by program component. Further, we
explored the relationship between the calculated average
cost per woman served and the number of women served.
RESULTS
During the 1-year period, the NBCCEDP as a whole
served 1.02 million women at a total cost of $255.53 mil-
lion, not counting the estimated value of in-kind dona-
tions (Table 1). Individual NBCCEDP grantees served an
average of 16,135 women (SD, 30,165) at an average cost
of $4.06 million (SD, $6.41 million). The weighted mean
cost per woman served excluding the value of in-kind
donations was $251.38 (SD, $76.90), of which $144.53
(SD, $38.12) was for clinical services. The total weighted
mean cost per woman served including the $45.05 (SD,
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$73.89) estimated value of in-kind donations was
$296.44 (SD, $122.55).
Table 2 presents the weighted mean outcomes and
costs for breast and cervical cancer screening in the pro-
gram. For breast cancer, the calculated average number of
women screened by these programs with only CDC funds
was 4509 (SD, 4186) and with CDC and non-CDC
funds was 7850 (SD, 21,520). For cervical cancer, these
estimates were 4858 (SD, 5778) with CDC funds and
6056 (SD, 8220) with and without CDC funds.
Using the weighted mean approach, the cost of
screening with an office visit was $109.77 (SD, $43.80)
for breast cancer and $61.38 (SD, $24.82) for cervical
cancer (Table 2). Without an office visit, the weighted
mean cost was $88.44 (SD, $31.23) for breast cancer and
$20.62 (SD, $18.86) for cervical cancer. The weighted
mean cost of a diagnostic procedure was $400.68 (SD,
$128.39) for breast cancer and $415.16 (SD, $347.13)
for cervical cancer. The estimated distribution of weighted
mean cost and percent distribution per woman served by
a program component is presented in Figure 2. Screening
and diagnostic services accounted for the highest cost, of
$144.53 (SD, $38.12), which represented 57.5% of total
program costs per woman served (Fig. 2). Patient sup-
port/case management was the second highest, with an
estimated weighted average cost of $27.90 (SD, $30.04)
per woman served (11.1% of the total costs). Program
management was the third highest, with an estimated
weighted average cost of $25.16 (SD, $18.44) per woman
served (10.0% of the total costs).
TABLE 1. Estimated Outcomes and Costs Among 63a Recipients of CDC Funds for NBCCEDP Activities Dur-
ing 2006/2007 Fiscal Year
Program Outcomes
Total number of women served 1,016,492
Mean number served (SD) 16,135 (30,165)
Median number served (25th, 75th percentiles) 10,963 (4043, 17,504)
Program Costs With In-Kind Donations Without In-Kind Donations
Total program costs, in millions of $ 301.33 255.53
Mean cost per program (SD), in millions of $ 4.78 (6.90) 4.06 (6.41)
Median cost per program (25th, 75th percentiles), in millions of $ 3.21 (1.50, 5.05) 2.46 (1.23, 4.60)
Weighted mean cost per woman served (SD), $ 296.44 (122.55) 251. 38 (76.90)
Weighted Mean cost of clinical services per woman servedb (SD), $ — 144.53 (38.12)
Mean value of in-kind donations per woman servedc (SD), $ 45.05 (73.89) —
Abbreviations: CDC, Centers for Disease Control and Prevention; NBCCEDP, National Breast and Cervical Cancer Early Detection Program; SD, standard
deviation.
a Three recipients of CDC funds did not meet data quality criteria for this analysis.
b Clinical services include screening and diagnostic services.
c In-kind donations are defined as those contributions that strictly represent opportunity cost.
TABLE 2. Weighted Mean Outcomes and Costs for Breast and Cervical Cancer Screening in the Program
During 2006/2007 Fiscal Year
Breast Cancer Screening,
Weighted Mean (SD)
Cervical Cancer Screening,
Weighted Mean (SD)
Program outcome
Women screened with NBCCEDP funds 4,509 (4,186) 4,858 (5,778)
Women screened with all funds (ie, CDC 1 non-CDC funds) 7,850 (21,520) 6,056 (8,220)
Women receiving diagnostic follow-up visits for abnormal results 1,969 (2,998) 491 (619)
Program cost ($)a
Cost of screening with an office visit 109.77 (43.80) 61.38 (24.82)
Cost of a diagnostic procedure 400.68 (128.39) 415.16 (347.13)
Cost of screening mammography without an office visitb 88.44 (31.23) —
Cost of Pap smear without an office visitc — 20.62 (18.86)
a Two programs were dropped from these calculations because of insufficient screening data.
bNo data on the number of mammograms that were performed using non-CDC funds were available, so this calculation includes only the 28 programs with
complete data that did not perform any mammograms using non-CDC funds.
c No data on the number of Pap tests that were performed using non-CDC funds was available, so this calculation includes only the 33 programs with com-
plete data that did not perform any Pap tests using non-CDC funds.
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As shown in Table 3, we estimated that 5687 cases
of breast cancer were detected during the study period by
the 63 NBCCEDP grantees whose data we analyzed, an
average of 90.3 cases (SD, 117.2) per grantee, and that the
weighted mean cost per cancer case detected was $35,480.
We estimated that grantees detected an average of 83.2
cases of cervical cancer (SD, 111.9) and that the weighted
mean cost per cancer case detected was $18,995. As shown
in Figure 3, data suggest that grantees’ average cost of
detecting a case of cancer appears to decline as the total
number of women they served increases.
DISCUSSION
Excluding the value of in-kind donations, we estimated
that the weighted average cost of the NBCCEDP per
woman served was $251 and that the weighted average
cost of clinical services per woman served was $145.
Including the value of in-kind donations, we estimated
that the weighted average cost was $296 per woman
served. We also estimated that the weighted average cost
of screening for breast cancer was $110 with an office visit
and $88 without, that the average cost of the breast cancer
diagnostic procedure was $401, and that the cost per case
of breast cancer detected was $35,480. For cervical cancer,
we estimated that corresponding costs were $61, $21,
$415, and $18,995, respectively. In an era of constrained
resources for public health programs, these cost estimates
calculated directly from NBCCEDP can provide useful
information for program planning and budget allocation.
Lack of cost information directly obtained from a
Figure 2. Estimated Distribution of Weighted Mean Costs and Percent Distribution per Woman Served, by Program Component.
Estimates exclude the value of in-kind contributions, the numbers in parentheses are standard deviation, and the numbers in
brackets are % distribution of cost per woman served by program component.
TABLE 3. Number of Cancer Cases Detected and Cost per Cancer Detected by the NBCCEDP During
2006/2007 Fiscal Year
Breast Cancers Detected Number of Cancers Detected Mean Cancers Detected (SD)
All breast cancer 5687 90.3 (117.2)
Carcinoma in situ 1467 23.3 (34.0)
Invasive cancer 4220 67.0 (89.3)
Cost per Breast Cancer Detected Median by Program (IQR), $ Weighted Mean, $a
All breast cancer 39,769 (31,538-52,693) 35,480
Carcinoma in situ 174,398 (104,991-248,704) 137,543
Invasive cancer 54,896 (42,081-84,549) 47,814
Cervical Cancers Detected Number of Cancers Detected Mean Cancers Detected (SD)
All cervical cancer 5241 83.2 (111.9)
High-grade cervical intraepithelial neoplasiab 4981 79.1 (108.3)
Invasive cancer 260 4.1 (4.5)
Cost per cervical cancer detected Median by Program (IQR), $ Weighted Mean, $a
All cervical cancer 27,230 (12,377-54,346) 18,995
High-grade cervical intraepithelial neoplasiab 31,131 (13,040-64,039) 19,986
Invasive cancer 465,425 (206,028-972,478) 382,892
aMean calculated by dividing costs for all programs divided by cancers detected for all programs. Standard deviation not included because some programs
did not detect any cancers.
bHigh-grade cervical intraepithelial neoplasia (CIN) includes CIN2, CIN3, carcinoma in situ, and adenocarcinoma in situ.
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program is often a limiting factor in using such data to
make realistic policy decisions in public health programs.
These cost estimates provide a baseline against which
future NBCCEDP cost estimates can be assessed.
As mentioned earlier, these cost estimates update
our previous estimates of NBCCEDP costs that were
based on data from 9 grantees.9 In general, these updated
cost estimates were slightly higher than those we reported
previously. Other previous estimates of the cost of mam-
mography screening during an office visit have ranged
from $73 to $170 when adjusted to 2007 dollars,12-15 and
other previous estimates for a Pap test during an office
visit have ranged from $48 to $118 (in 2007 dollars).16-20
Although cost estimates from different studies are difficult
to compare because of differences in cost estimation
methods, study objectives, viewpoint of the analysis, and
study settings,21 our estimates of per-person cost of serv-
ices provided by the NBCCEDP are within the range of
previous estimates. For example, previous estimates of the
cost of a diagnostic procedure for breast cancer have
ranged from $351 to $374,12,14 whereas we estimated
that the cost of a procedure in the NBCCEDP ranged
from $368 to $433. Although numerous studies have
assessed the costs of breast and cervical cancer screening
and diagnosis in the last decade,22,23 few studies have
assessed the cost of such preventive health services pro-
vided through public health programs designed for low-
income underserved populations.
The NBCCEDP is mandated by law to allocate about
60% of its resources to clinical services. In this study, we
found that 57.5% of the program resources (excluding the
value of in-kind donations) are allocated to clinical services,
indicating that program administrators are, on balance,
adhering to this mandate. The law mandates that the
remaining 40% of the program’s resources be used to sup-
port health promotion activities or other nonclinical activ-
ities essential to the success of clinical services. The
provision of resources for health promotional activities in
this program by policy makers is perhaps in recognition
that there are other factors that affect the ability of unin-
sured low-income women to receive cancer screening serv-
ices in addition to financial barriers. Studies have identified
these factors to include both patient and provider behav-
ior.24-27 For instance, studies have shown that the degree to
which patients seek cancer screening services is associated
with their usual source of care, public education, outreach/
recruitment, physician recommendation, and implementa-
tion of interventions to increase professional development
of preventive health among health providers.28-30 We esti-
mated that the NBCCEDP spends 2.9% of its resources on
public education, 2.9% on outreach/recruitment activities,
and 1.8% on professional development. These health pro-
motional activities are used to educate and improve the
knowledge, skills, and attitudes of the general public about
the importance of cancer prevention.
The NBCCEDP attempts to ensure that women
who have abnormal screening results receive timely diag-
nosis, affordable care, and treatment. We estimated that
for every woman served, the program spends $28 (11.1%
of its resources) in patient support/case management serv-
ices. These services are considered essential to helping
women with limited access to health care overcome bar-
riers to receiving services, adhere to screening recommen-
dations, receive timely diagnostic recommendations, and
make effective use of recommended treatment thera-
pies.31-34 Quantifying the amount of program resources
that the NBCCEDP allocates to different health promo-
tion activities is essential to ensuring that the program is
accountable for how it uses its resources to encourage
women to be screened and to help them obtain other rec-
ommended preventive health services.
The 2010 Affordable Care Act (ACA) is expected to
reduce financial barriers to preventive health services such
as cancer screening by expanding insurance coverage for
these services and eliminating copayments and deductibles
for millions of low-income Americans. Because many of
these newly insured people may have limited knowledge of
the health care system and thus may have difficulty access-
ing available services,35,36 health care workers trained in
health promotion activities can play an important role in
helping them obtain services. In the past 20 years, the
NBCCEDP has built a strong infrastructure and gained ex-
perience in using health promotion activities to help to
deliver cancer screening and diagnostic services to women
with limited access to the health care system. As the nation
Figure 3. Average Cost per Woman Served by Number of
Women Served in NBCCEDP during 2006/2007 Fiscal Year.
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implements the ACA, this infrastructure and experience
may be useful in helping newly insured people obtain rec-
ommended preventive health services. In addition, our esti-
mates of the cost of various NBCCEDP health promotion
activities (presented in Fig. 2) could be used as benchmarks
against which current and future expenditures for similar
services could be compared or as a guide for estimating the
financial resources required to provide such services for the
increased number of women who may have insurance cov-
erage as the result of the ACA.
However, extrapolations of our NBCCEDP cost
estimates to the much larger population of women
expected to become eligible to receive preventive health
care services under the ACA may overestimate the actual
cost of such services because the average cost of these serv-
ices may decline as the number of women served increases
(as suggested by data presented in Fig. 3). However, quan-
tifying the extent to which the per-person cost of service
provision may decrease as the number of women served
increases would require more years of program cost data
than we had available for this article.
In the past 20 years, NBCCEDP partners have
invested a substantial amount of their resources to this pro-
gram. We estimated that the value of in-kind donations to
the NBCCEDP by its partners amounted to $45 per
woman served, or 15% of the estimated $296 weighted av-
erage cost per woman served in the program. These in-kind
donations are a clear indication of the strong commitment
that NBCCEDP’s various partners have to the program
and have been instrumental in advancing the program’s
ultimate goal of providing all US women with access to
breast and cervical cancer screening, diagnosis, and treat-
ment services. On the other hand, we estimated that
NBCCEDP administrators spend approximately 1.1% of
its resources in developing, maintaining, and sustaining
relationships with its partners, which indicates that
NBCCEDP administrators understand the importance of
partner involvement to the success of this program.
Despite our concerted effort to ascertain the true
cost of delivering cancer screening services in publicly
funded cancer screening programs, there are 6 notable
limitations to our study. First, the cost data presented in
this article did not include cost of resources incurred by
women participating in this program. These resources
include transportation cost, child and dependent care
costs, value of time spent in traveling and receiving pre-
ventive cancer screening services, and psychosocial costs
such as anxiety from false-positive test results. As a result,
our estimates do not reflect the total societal cost of deliv-
ering cancer screening and related follow-up services
through a publicly funded program. However, this total
cost could be estimated easily by adding our estimates of
program costs to previously published estimates of perso-
nal costs incurred by program participants, such as the
estimate that women screened for breast cancer through
the NBCCEDP incurred average personal costs of $17
(range, $11-$23).37 Such estimates of the total societal
cost of specified health care services can be used by policy
makers for program planning and by researchers attempting
to estimate societal cost-effectiveness of the NBCCEDP.
Second, because we did not have another source of infor-
mation against which to check grantees’ reports of non-
CDC funding, we were unable to verify the accuracy of
these reports; any inaccuracies in these reports would obvi-
ously have affected the accuracy of our estimates of the total
cost of delivering cancer screening services in the program.
Third, because we analyzed only 1 year of data, our esti-
mates do not reflect variations in federal funding levels or
in the availability of other program resources. To produce
multiyear cost estimates that do reflect such variations, we
are currently collecting multiple years of program cost data.
Fourth, our assumption that the average costs of office visits
for breast and cervical screening were identical may have led
us to under- or overestimate the costs of screening for these
cancers. However, the results of previous studies suggest
that the impact of this assumption on our cost estimates
may have been minimal.12-20 Fifth, we did not allocate the
estimated value of in-kind donations to specific program
activities. Finally, because of the short duration of our study
period, we had to use an intermediate outcome measures
(eg, cases of cancer detected)21 rather than a long-term out-
come measure such as life-years gained. However, we are
currently conducting study designed to estimate life-years
gained through the NBCCEDP and have recently pub-
lished some findings from that study.38
These limitations notwithstanding, we believe that
the data presented in this article are important because they
provide primary information on the overall allocation of
NBCCEDP resources into various activities. This informa-
tion will be very useful for policy makers in determining
the amount of resources that may be needed in implement-
ing potential policy, systems, and environmental changes
in the program. For example, the results reported in this ar-
ticle could be used to estimate the amount of resources
required to implement a population-based organized breast
and cervical cancer screening program in the United States.
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